What is Quotient Switzerland?
Quotient Switzerland operates at the intersection of transfusion diagnostics and automated laboratory technology. With over three decades of industry experience, the company has developed MosaiQ, a proprietary multiplex microarray platform designed to consolidate testing modalities into a single, fully automated workflow. This innovation is engineered to drive operational efficiencies and cost reductions for clinical laboratories worldwide. Beyond its core diagnostic offerings, the company demonstrated its agility by rapidly deploying the MosaiQ COVID-19 Antibody Microarray, which secured both CE marking and U.S. FDA Emergency Use Authorization. Headquartered in Eysins, Switzerland, with significant operational footprints in Scotland and Pennsylvania, Quotient is uniquely positioned to influence the future of clinical diagnostics through its scalable, high-throughput testing solutions.
How much funding has Quotient Switzerland raised?
Quotient Switzerland has raised a total of $219M across 3 funding rounds:
Stock Offering
$40M
Debt
$84M
Stock Offering
$95M
Stock Issuance/Offering (2014): $40M, investors not publicly disclosed
Debt (2016): $84M led by Morgan Stanley & Co. LLC
Stock Issuance/Offering (2021): $95M, investors not publicly disclosed
Key Investors in Quotient Switzerland
Morgan Stanley & Co. LLC
A global financial services firm providing investment banking, securities, and wealth management services to a diverse client base.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Quotient Switzerland?
With the recent infusion of $95M, Quotient is well-positioned to accelerate the global adoption of its MosaiQ platform. The strategic focus will likely shift toward expanding the menu of tests available on the multiplex microarray system, thereby increasing its utility in diverse clinical settings. As the company navigates the post-pandemic diagnostic landscape, the integration of its technology into standard laboratory workflows remains a primary objective. Investors will be monitoring the firm's ability to convert its technological superiority into sustained market share, particularly as it seeks to optimize its global supply chain and enhance its commercial reach across international healthcare markets.
See full Quotient Switzerland company page
